Celltrion Biopharmaceutical Plant, Incheon, South Korea
Key Data:
Order year
November 2002
Location
Songdo New City, Incheon, South Korea
Estimated investment
$85m
Completion
2005, validation to be carried out in early 2006 with full production by mid 2006
Expansion
Phase two of the plant to give an additional 180,000l of capacity is expected to be complete by 2010
Output chemicals
Vaccines, protein therapeutics and monoclonal antibodies
Key Players:
Sponsor
Celltrion (Vaxgen is no longer involved having sold its interest in the company)
Lead engineer / designer
Fluor Enterprises, Daewoo Engineering and Construction, BioEngineering, Foster Wheeler
Other contractors
Emerson Process Management, Amersham, Millipore
Validation
Fluor Enterprises, VaxGen QA
Financing
Vaxgen (48%), Nexol and Nexol Biotech (13%), Korean Tobacco and Ginseng (13%), J. Stephen and Co Ventures (13%) and others (8%)
